AN2 Therapeutics Inc (ANTX)
2.48
-0.07
(-2.75%)
USD |
NASDAQ |
May 08, 14:16
AN2 Therapeutics Cash from Investing (Quarterly): 0.42M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.42M |
| September 30, 2023 | -62.46M |
| June 30, 2023 | 7.877M |
| March 31, 2023 | 10.89M |
| December 31, 2022 | 6.055M |
| September 30, 2022 | -2.317M |
| Date | Value |
|---|---|
| June 30, 2022 | -39.49M |
| March 31, 2022 | 13.98M |
| December 31, 2021 | 6.246M |
| September 30, 2021 | -6.986M |
| June 30, 2021 | -49.28M |
| March 31, 2021 | 0.00 |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-62.46M
Minimum
Sep 2023
13.98M
Maximum
Mar 2022
-9.589M
Average
0.21M
Median
Cash from Investing (Quarterly) Benchmarks
| Gilead Sciences Inc | -2.207B |
| QuidelOrtho Corp | -55.10M |
| CymaBay Therapeutics Inc (DELISTED) | -42.11M |
| Insmed Inc | 1.803M |
| Revance Therapeutics Inc | 2.37M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -17.07M |
| Cash from Financing (Quarterly) | -0.321M |
| Free Cash Flow | -53.29M |
| Free Cash Flow Per Share (Quarterly) | -0.5727 |
| Free Cash Flow Yield | -91.11% |